- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal AntibodyNot yet recruitingNCT07445815Phase 2
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.RecruitingNCT07377175Phase 1
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionEnrolling by invitationNCT07149454Phase 1
Sponsor listed in the registry: Lanzhou Institute of Biological Products Co., Ltd · First submitted after Lanzhou Institute of Biological Products Co., Ltd became part of Sinopharm
- Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term InfantsNot yet recruitingNCT07363837Phase 1/2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell CarcinomaRecruitingNCT06194656Phase 2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveNot yet recruitingNCT07327398Phase 2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT07338851
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveRecruitingNCT07302256Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.RecruitingNCT06298071Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor PatientsRecruitingNCT06990464Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.RecruitingNCT07205198Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.RecruitingNCT06298058Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.RecruitingNCT06512116Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy IndividualsRecruitingNCT06932523Phase 1/2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor PatientsRecruitingNCT06985368Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the CongoNot yet recruitingNCT07253675Phase 2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trial of SIBP-A16 Injection in Healthy AdultsRecruitingNCT07106918Early Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live VaccineRecruitingNCT06771479Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 YearsActive, not recruitingNCT05262010Phase 3
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule BridgingActive, not recruitingNCT06632912Phase 3
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)CompletedNCT05916326Phase 3
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19CompletedNCT04869592Phase 1/2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and AboveCompletedNCT05408312Phase 1
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 3
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedActive, not recruitingNCT05091619Phase 3
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.CompletedNCT06342349Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03755427Phase 2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03369808Phase 1/2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Trial of A Quadrivalent Influenza VaccineCompletedNCT03744104Phase 3
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study Exploring Efficacy of Peginterferon in Patients With Herpes ZosterCompletedNCT05492591Phase 2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study Comparing SIBP-04 and Bevacizumab in Healthy Male SubjectsCompletedNCT04135898Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldCompletedNCT05158777Phase 3
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.CompletedNCT05203601Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung CancerCompletedNCT05318443Phase 3
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT04361279Phase 3
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast CancerCompletedNCT03989037Phase 3
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic HyperuricemiaCompletedNCT05302388Phase 1
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 YearsCompletedNCT04072497Phase 1/2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- Clinical Trial of Quadrivalent Influenza Virus Split VaccineCompletedNCT04363359Phase 2
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, LiveCompletedNCT05161845Phase 4
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 YearsCompletedNCT05138705Phase 4
Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm
- A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of AgeActive, not recruitingNCT05839301Phase 3
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella VaccineActive, not recruitingNCT05669625Phase 3
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), InactivatedActive, not recruitingNCT04863638Phase 4
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and AboveActive, not recruitingNCT05365724Phase 1/2
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and AboveCompletedNCT04917523Phase 3
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and AboveActive, not recruitingNCT05382871Phase 3
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AboveCompletedNCT04510207Phase 3
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and AboveActive, not recruitingNCT05374954Phase 3
Sponsor listed in the registry: China National Biotec Group Company Limited · First submitted after China National Biotec Group Company Limited became part of Sinopharm
- A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)Status unknownNCT05293548Phase 2
Sponsor listed in the registry: National Vaccine and Serum Institute, China · First submitted after National Vaccine and Serum Institute, China became part of Sinopharm